Yutaka Motomura

Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker

Tetsuya Nakatsura, Yoshihiro Yoshitake, Satoru Senju et al. · Biochemical and Biophysical Research Communications · 2003 · 432 citations

Medicine, Cancer Biology, Oncology +14

Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

Yu Sawada, Toshiaki Yoshikawa, Daisuke Nobuoka et al. · Clinical Cancer Research · 2012 · 299 citations

Medicine, Immunology, Oncology +17

Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma

Hiroyuki Komori, Tetsuya Nakatsura, Satoru Senju et al. · Clinical Cancer Research · 2006 · 174 citations

Life Sciences, Immunology, Oncology +15

HLA‐A2‐restricted glypican‐3 peptide‐specific CTL clones induced by peptide vaccine show high avidity and antigen‐specific killing activity against tumor cells

Toshiaki Yoshikawa, Munehide Nakatsugawa, Shiro Suzuki et al. · Cancer Science · 2011 · 77 citations · Full text

Life Sciences, Immunology, Oncology +17

Embryonic Stem Cell–Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10

Yutaka Motomura, Satoru Senju, Tetsuya Nakatsura et al. · Cancer Research · 2006 · 69 citations · Full text

Life Sciences, Immunology, Oncology +17